These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10721092)

  • 41. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-tryptophan: eosinophilia-myalgia syndrome.
    D'Arcy PF
    Adverse Drug React Toxicol Rev; 1995; 14(1):37-43. PubMed ID: 7612781
    [No Abstract]   [Full Text] [Related]  

  • 43. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).
    De Schryver-Kecskemeti K; Bennert KW; Cooper GS; Yang P
    Dig Dis Sci; 1992 May; 37(5):697-701. PubMed ID: 1563309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
    Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
    Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
    Daniels SR; Hudson JI; Horwitz RI
    J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report.
    Smith E; Gordon M; Lebwohl M
    Cutis; 2006 Jun; 77(6):361-4. PubMed ID: 16838769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Latham P; Schwartz A
    Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287
    [No Abstract]   [Full Text] [Related]  

  • 50. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome.
    Ko SM; Park JE; Heo IK; Shin YU; Kim YH; Son WC
    Food Chem Toxicol; 2023 Sep; 179():113946. PubMed ID: 37453474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Contaminants in biotechnologically manufactured L-tryptophan.
    Simat T; van Wickern B; Eulitz K; Steinhart EH
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased type I collagen gene expression in L-tryptophan associated eosinophilia-myalgia syndrome skin fibroblasts.
    Varga J; Li L; Jimenez SA
    J Rheumatol; 1993 Aug; 20(8):1303-8. PubMed ID: 8230009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study.
    McKeon P; Swanwick G; Manley P
    Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and analysis of contaminants in ems-related tryptophan.
    Steinhart H; van Wickern B; Meyer K; Simat T
    Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
    [No Abstract]   [Full Text] [Related]  

  • 59. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 60. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.